News

DOYLESTOWN, PA, April 26, 2022 – Antios Therapeutics, Inc. (Antios), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus ... » Full Release

ATI-2173 demonstrated potent hepatitis B virus (HBV) DNA suppression ATI-2173, in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated with alanine aminotransferase (ALT) normalization ... » Full Release

MENDHAM, N.J. and WARMINSTER, Pa., December 14, 2021 – Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient ... » Full Release

MENDHAM, N.J., Dec. 6, 2021 — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus ... » Full Release

MENDHAM, N.J. and ROME, ITALY November 15, 2021 – Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic ... » Full Release

- Financing round was co-led by GordonMD Global Investment LP - Funding will support the Phase 2b clinical program of ATI-2173 in HBV MENDHAM, N.J., Nov. ... » Full Release

MENDHAM, N.J., and SOUTH SAN FRANCISCO, Calif., October 19, 2021 – Antios Therapeutics, Inc. and Assembly Biosciences, Inc. (Nasdaq: ASMB) today announced that the companies ... » Full Release

MENDHAM, NJ, October 7, 2021 – Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus ... » Full Release

MENDHAM, NJ, September 22, 2021 – Antios Therapeutics, Inc. (“Antios”) today announced that Douglas Mayers, M.D., Chief Medical Officer and Co-Founder of Antios, will be giving ... » Full Release

ATLANTA, Aug. 10, 2021 (GLOBE NEWSWIRE) — Antios Therapeutics, Inc. (“Antios”) today announced the appointment of Catherine Coffey Ross as Vice President, Medical Affairs. Ms. ... » Full Release

MENDHAM, N.J. and WARMINSTER, Pa., – Antios Therapeutics, Inc. and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the companies have entered into a clinical ... » Full Release

Antios Therapeutics, Inc. (“Antios”) today announced pharmacokinetic (PK), safety and efficacy data from a Phase 1b clinical trial of ATI-2173, the Company’s Active Site Polymerase Inhibitor Nucleotide (ASPIN), inchronic HBV-infected adult patients. » Full Release

HBV-TAG: Presentation of in vitro antiviral activity and Phase 1a healthy volunteer data demonstrating the safety, tolerability, and favorable pharmacokinetics of multiple ascending doses of ATI-2173 Pharmacokinetics, ... » Full Release

Responsible for managing clinical development and the regulatory processes for ATI-2173, an ASPIN, which is in development as part of a potential curative regimen for ... » Full Release

SAVE 1 to evaluate ATI-2173 in combination with tenofovir (TDF) vs. TDF plus placebo SAVE 1 to include cohort of Hepatitis Delta Virus (HDV) co-infected subjects to assess ATI-2173 activity against HDV MENDHAM, N.J., April 21, 2021 (GLOBE NEWSWIRE) – Antios Therapeutics, Inc. (“Antios”) today announced that it has dosed the first patients in its Sustained Anti-Viral Efficacy (SAVE) clinical trial, a Phase 2a study of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN) in clinical development as a backbone of a potentially curative regimen for chronic HBV. » Full Release

Funding will support the Phase 2 clinical program of ATI-2173 in HBV Soleus Capital led the round with new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling Capital as well as Altium Capital, Amzak Health, Granite Point Capital Management, LP, and Life Sci Venture Partners and participating existing investors Lumira Ventures, Cam Capital, Delos Capital, Domain Associates and Sixty Degree Capital MENDHAM, N.J., April 12, 2021 (GLOBE NEWSWIRE) – Antios Therapeutics, Inc.  » Full Release

ATLANTA, Feb. 17, 2021 (GLOBE NEWSWIRE) – Antios Therapeutics, Inc. (“Antios”) today announced the appointment of seasoned financial executive, Tamra J. Adams, as the Company’s chief financial officer (CFO) effective March 1, 2021. Ms. Adams fills a newly created executive position at Antios as part of the Company’s rapid development. “We have recently completed a Phase 1b clinical trial of our lead asset, ATI-2173, a potential backbone treatment in a functional curative regimen for chronic HBV infection, and anticipate presenting proof-of-concept data from the study in mid-2021,” said Gregory Mayes, chief executive officer of Antios. » Full Release

Former biopharmaceutical executive has been at the forefront of developing treatments for infectious diseases of the liver including HBV and HCV ATLANTA, GA, Feb. 11, ... » Full Release

Study results expected to be presented in mid-2021 ATLANTA, GA, Jan. 25, 2021 (GLOBE NEWSWIRE) – Antios Therapeutics, Inc. (“Antios”) today announced that it has ... » Full Release

Former CEO and Antios co-founder, Abel De La Rosa, Ph.D., appointed Chairman of the Board of Directors Mayes to lead continued development of ATI-2173 as ... » Full Release

ATLANTA, GA, Sept. 3, 2020 /PRNewswire/ – Antios Therapeutics, Inc. (“Antios”), a biopharmaceutical company focused on the development of innovative therapies to treat and cure ... » Full Release

ATLANTA, GA, Sept. 1, 2020 /PRNewswire/ – Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and ... » Full Release

ATLANTA, GA, Feb. 24, 2020 /PRNewswire/ – Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and ... » Full Release

ATLANTA, GA, Feb. 12, 2020 /PRNewswire/ – Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and ... » Full Release

ATLANTA, GA, Dec. 9, 2019 /PRNewswire/ – Antios Therapeutics, Inc. (“Antios”), a biopharmaceutical company focused on the development of innovative therapies to treat and cure ... » Full Release

Antios raises $25 million in Series A financing Drug Innovation Ventures at Emory (DRIVE) today announced the licensing of ATI-2173, its leading candidate for the ... » Full Release

International Group of Investors from Canada, the U.S. and China Support Former Senior Executives from Pharmasset and Idenix in New Venture ATLANTA, GA, Nov. 27, ... » Full Release